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Background: Some physicians are still concerned about the safety of treatment at home of patients with acute deep venous
thrombosis (DVT).
Methods:We used data from the RIETE (Registro Informatizado de la Enfermedad TromboEmbólica) registry to compare
the outcomes in consecutive outpatients with acute lower limb DVT according to initial treatment at home or in the
hospital. A propensity score-matching analysis was carried out with a logistic regression model.
Results: As of December 2012, 13,493 patients had been enrolled. Of these, 4456 (31%) were treated at home. Patients
treated at home were more likely to be male and younger and to weigh more; they were less likely than those treated in the
hospital to have chronic heart failure, lung disease, renal insufﬁciency, anemia, recent bleeding, immobilization, or cancer.
During the ﬁrst week of anticoagulation, 27 patients (0.20%) suffered pulmonary embolism (PE), 12 (0.09%) recurrent
DVT, and 51 (0.38%) major bleeding; 80 (0.59%) died. When only patients treated at home were considered, 12 (0.27%)
had PE, 4 (0.09%) had recurrent DVT, 6 (0.13%) bled, and 4 (0.09%) died (no fatal PE, 3 fatal bleeds). After propensity
analysis, patients treated at home had a similar rate of venous thromboembolism recurrences and a lower rate of major
bleeding (odds ratio, 0.4; 95% conﬁdence interval, 0.1-1.0) or death (odds ratio, 0.2; 95% conﬁdence interval, 0.1-0.7)
within the ﬁrst week compared with those treated in the hospital.
Conclusions: In outpatients with DVT, home treatment was associated with a better outcome than treatment in the
hospital. These data may help safely treat more DVT patients at home. (J Vasc Surg 2014;59:1362-7.)Current guidelines of antithrombotic therapy recom-
mend initial treatment of patients with acute deep venous
thrombosis (DVT) with low-molecular-weight heparin
(LMWH), fondaparinux, or unfractionated heparin (UFH)
over no such initial therapy.1 A number of studies com-
paring LMWH administered at home (without hospital
admission or after early discharge) with UFH in the hos-
pital suggested that home therapy may be associated with
improved outcome and better quality of life.2-12 Hence,
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2current guidelines recommend that most patients with
DVT be initially treated at home rather than in the hospi-
tal.1 However, many physicians are still concerned about
the safety of home therapy because even with adequate
anticoagulation, some patients may present with symptom-
atic pulmonary embolism (PE), recurrent DVT, major
bleeding complications, or even death.
The RIETE (Registro Informatizado de la Enfermedad
TromboEmbólica) registry is an ongoing, international
(Spain, France, Italy, Israel, Germany, Switzerland, Repub-
lic of Macedonia, and Brazil), multicenter, prospective reg-
istry of consecutive patients presenting with symptomatic
acute venous thromboembolism (VTE). It started in Spain
in 2001, and some years later, the database was translated
into English to expand the Registry to other countries,
with the aim to help physicians worldwide select the
most appropriate therapy for their patients. Data from
this registry have been used to evaluate outcomes after
acute VTE, such as the frequency of recurrent VTE, major
bleeding, and mortality, and risk factors for these out-
comes.13-16 The current analysis compared the outcome
of outpatients with acute DVT of the lower limbs within
the ﬁrst week of anticoagulation according to initial therapy
at home or in the hospital.
METHODS
Consecutive patients presenting with symptomatic
acute DVT conﬁrmed by objective tests (compression ul-
trasonography or contrast venography) were enrolled in
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participating in a therapeutic clinical trial with a blinded
therapy. All patients (or their relatives) provided written
or oral consent for participation in the registry, in accor-
dance with local ethics committee requirements.
In the RIETE registry, participating physicians ensured
that eligible patients were consecutively enrolled. Data
were recorded onto a computer-based case report form at
each participating hospital and submitted to a centralized
coordinating center through a secure website. The study
coordinating center assigned patients a unique identiﬁca-
tion number to maintain patient conﬁdentiality and was
responsible for all data management. Data quality was
regularly monitored electronically, including checks to
detect inconsistencies or errors, which were resolved by
contacting the local coordinators. Data quality was also
monitored by periodic visits to participating hospitals by
contract research organizations that compared the submit-
ted data with medical records.
Study design. For this study, all outpatients with acute
DVT in the lower limbs, with no respiratory symptoms
suggesting PE, and initially treated with LMWH or fonda-
parinux were considered. Those initially treated with UFH,
thrombolytics, rivaroxaban, or dabigatran were excluded;
also excluded were those undergoing an inferior vena
cava ﬁlter and those not receiving anticoagulation. Home
therapy was considered when patients spent less than
24 hours in the hospital from their arrival to the emergency
department. The major outcome for this study was the
development of symptomatic and objectively conﬁrmed
PE, recurrent DVT, major bleeding, or death within the
ﬁrst 7 days of treatment. Secondary outcomes were fatal
PE or fatal bleeding appearing within the ﬁrst 7 days.
Recurrent DVT was deﬁned as either the extension of
the index DVT (in the ipsilateral leg) or a new DVT
appearing in the contralateral leg. In the absence of au-
topsy, fatal PE was deﬁned as any death within 10 days
of a conﬁrmed PE diagnosis, in the absence of any alterna-
tive cause of death. Fatal bleeding was deﬁned as any death
occurring within 10 days of a major bleeding episode, in
the absence of an alternative cause of death. Major
bleeding was deﬁned as an overt bleed that required a
transfusion of 2 units or more of blood; was retroperito-
neal, spinal, or intracranial; or was fatal.
Baseline variables. The following clinical variables
were recorded when the qualifying episode of DVT was
diagnosed: patient’s sex, age, and body weight; presence
of coexisting conditions, such as chronic heart or lung dis-
ease; recent (<30 days before DVT) major bleeding; pres-
ence of risk factors for DVT, including active cancer
(deﬁned as newly diagnosed cancer or cancer that is being
treated [ie, surgery, chemotherapy, radiotherapy, hormonal
or support therapy]), recent immobilization (deﬁned as
nonsurgical patients who were conﬁned to bed with bath-
room privileges for $4 days in the 2 months before DVT
diagnosis), and surgery (deﬁned as those who had under-
gone surgery in the 2 months before DVT); extent of the
DVT (distal DVT was DVT conﬁned to the infrapoplitealveins); and laboratory data, including whole blood cell
counts and serum creatinine clearance levels. Creatinine
clearance levels at baseline were measured according to
the Cockcroft and Gault formula.17
Treatment and follow-up. In RIETE, there was no
standardization of treatment, and patients were managed
according to the clinical practice of each participating hos-
pital. The type, dose, and duration of anticoagulant therapy
were recorded. Patients were followed up for at least
3 months in the outpatient clinic. During each visit, any
signs or symptoms suggesting DVT or PE recurrences or
bleeding complications were recorded. Each episode of
clinically suspected PE or recurrent DVT was investigated
by repeated ultrasonography, contrast venography, lung
scanning, helical computed tomography, or pulmonary
angiography as appropriate. Most outcomes were classiﬁed
as reported by the clinical centers, but if staff at the coordi-
nating center were uncertain how to classify a reported
outcome, that event was reviewed by a central adjudicating
committee (<10% of events).
Statistical analysis. We used Student t-test and c2 test
(or Fisher exact test where appropriate) to compare contin-
uous and categorical variables, respectively, between pa-
tients treated at home and those treated in the hospital.
We then carried out a propensity score-matching analysis
by a logistic regression model including the clinical charac-
teristics of the patients, risk factors for VTE, and underly-
ing diseases to get the propensity score to be treated at
home vs in the hospital.18-20 With use of the psmatch2
for Stata program, 4455 patients treated at home (of 4456)
were matched with those treated in the hospital. We carried
out a greedy method (nearest neighbor method) to get the
unbiased matched pairs of patients with a ratio of 1:1
(1 case [home therapy] and 1 control [in hospital] were
matched) without replacement, using a caliper of 0.2 times
the standard deviation of propensity score. Propensity score
matching is optimal to produce the largest similarity within
matched groups, but because matching on the propensity
score may not balance for unobserved confounders, a
sensitivity analysis was performed evaluating several caliper
widths iteratively until between-group standardized dif-
ferences were minimized. To validate the success of the
matching procedure, standardized differences were mea-
sured (in percentage points) in observed confounders
between matched groups.
Finally, we carried out a multivariable analysis through
a conditional logistic regression model with all matched
pairs to determine whether home therapy (vs in hospital)
was independently associated with a worse outcome at 7
and 90 days. We calculated adjusted odds ratios (ORs)
(and 95% conﬁdence intervals [CIs]) by controlling for
relevant covariates by means of multiple logistic regression
analysis. Covariates entering in the model were selected by
a signiﬁcance level of P < .20 on univariable analysis or by a
well-known association reported in the literature. We did
not include the dose of LMWH received because its choice
was expected to have been inﬂuenced by the physician’s
assessment of a patient’s risk of bleeding or recurrent
Fig. Annual rates of patients treated at home or in the hospital over time.
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follow-up that were not available at baseline. We used
SPSS software (version 20; SPSS Inc, Chicago, Ill) and
Stata program (with the psmatch2 package; Leuven E, Sia-
nesi B. PSMATCH2: Stata module to perform full Maha-
lanobis and propensity score matching, common support
graphing, and covariate imbalance testing. 2003) for the
statistical management of the data, and considered a two-
sided P < .05 to be statistically signiﬁcant.
RESULTS
As of December 2012, 44,085 VTE patients were
enrolled in RIETE. Of these, 13,742 were outpatients pre-
senting with acute DVT in the lower limbs and no respira-
tory symptoms suggesting PE. As initial therapy, 13,271
(97%) patients received LMWH, 222 (1.6%) fondaparinux,
218 (1.6%) UFH, 19 rivaroxaban, and 12 thrombolytics.
In all, 13,493 (31%) patients received initial therapy with
LMWH or fondaparinux and did not undergo a vena
cava ﬁlter. They were the subject for the current analysis.
Overall, 4456 patients (33%) were treated at home
with no hospital admission. For patients admitted to the
hospital, mean duration of hospital stay was 10.5 days
(95% CI, 8.5-12.5). Median duration was 6 days (inter-
quartile range, 0-12 days).The proportion of patients
treated at home progressively increased over time, but
one in every two patients was still initially treated in the
hospital in 2012 (Fig). Patients treated at home were
more likely to be male and signiﬁcantly younger and to
weigh more; they were less likely to have chronic heart fail-
ure, chronic lung disease, renal insufﬁciency, anemia,
recent major bleeding, recent immobilization, or cancer
(Table I). The majority of patients in both groups (97%
vs 99%) received initial therapy with LMWH; then, most
(71% vs 74%) switched to vitamin K antagonists. Interest-
ingly, patients treated at home were treated with lower
daily doses of LMWH than were those treated in the hos-
pital. The duration of LMWH use was longer in patients
initially treated at home than in those admitted to the hos-
pital; mean values were 14 6 26 days vs 11 6 36 days (P <
.001). Median values were 8 vs 7 days (P < .001).On logistic regression analysis, the following variables
were found to inﬂuence the decision to treat patients at
home vs in the hospital (C-statistic value, 0.68; 95% CI,
0.67-0.69): age, chronic lung disease, renal insufﬁciency,
anemia, leukocytosis, recent major bleeding, recent immo-
bilization $4 days, prior VTE, proximal DVT, and year of
diagnosis. After propensity score matching, all these vari-
ables became similar in both groups.
Overall, 27 patients (0.20%) experienced symptomatic
PE (7 were fatal), 12 (0.09%) had recurrent DVT, 51
(0.38%) bled (13 were fatal), and 80 (0.59%) died within
the ﬁrst week of therapy (Table II). Patients treated at
home had a signiﬁcantly lower rate of major bleeding
events (OR, 0.3; 95% CI, 0.1-0.6) and a lower mortality
(OR, 0.1; 95% CI, 0.04-0.3) than those treated in the
hospital had, with a similar rate of VTE recurrences.
Among 4456 DVT patients treated at home, 4 (0.09%)
died within the ﬁrst 7 days; 3 died of bleeding, 1 of dissem-
inated malignant disease. Among 9037 patients initially
treated in the hospital, 76 (0.84%) died within the ﬁrst
week. The causes of death were as follows: disseminated
cancer, 23; respiratory insufﬁciency, 13; infection, 9;
bleeding, 7; PE, 6; bronchoaspiration, 4; renal insufﬁ-
ciency, 2; heart failure, 2; sudden unexpected death, 2; mul-
tiorgan failure, 2; myocardial infarction, 1; bowel occlusion,
1; unknown, 4. During the ﬁrst 3 months, 95 patients
(0.70%) had developed PE (21 were fatal), 139 (1.03%)
had recurrent DVT, 188 (1.39%) bled (43 were fatal),
and 672 (4.98%) died. Patients treated at home still had a
signiﬁcantly lower rate of major bleeding and a lower mor-
tality than those treated in the hospital had. In addition, the
rate of fatal PE was also signiﬁcantly lower at 90 days in
patients treated at home (OR, 0.1; 95% CI, 0.01-0.8).
After propensity analysis, patients receiving treatment at
home had a signiﬁcantly lower rate of major bleeding com-
plications (OR, 0.4; 95% CI, 0.1-1.0) and a lower mortality
(OR, 0.2; 95% CI, 0.1-0.7) during the ﬁrst week compared
with those treated in the hospital (Table III). At the end of
the third month, patients treated at home had a signiﬁcantly
lower rate of fatal PE (OR, 0.1; 95% CI, 0.01-0.9) and a
lower mortality (OR, 0.4; 95% CI, 0.3-0.5).
Table I. Clinical characteristics and treatment, according to therapy in the hospital or at home
Home therapy (n ¼ 4456) In-hospital therapy (n ¼ 9037) OR (95% CI) P value
Clinical characteristics
Gender, male 2412 (54) 4611 (51) 1.1 (1.1-1.2) .001
Age, years 62 6 17 66 6 18 d <.001
Body weight, kg 77 6 15 74 6 15 d <.001
Underlying conditions
Chronic heart failure 151 (3.4) 388 (4.3) 0.8 (0.6-0.9) .01
Chronic lung disease 303 (6.8) 846 (9.4) 0.7 (0.6-0.8) <.001
Creatinine clearance levels, mL/min 82 6 35 71 6 33 d <.001
Anemia 1084 (24) 3047 (34) 0.6 (0.6-0.7) <.001
Recent major bleeding 24 (0.5) 103 (1.2) 0.5 (0.3-0.7) .001
Risk factors for VTE
Postoperative 378 (8.5) 806 (8.9) 0.9 (0.8-1.1) .40
Immobility $4 days 894 (20) 2311 (26) 0.7 (0.7-0.8) <.001
Cancer 769 (17) 1775 (20) 0.9 (0.8-0.9) .001
None of the above 2643 (59) 4732 (52) 1.3 (1.2-1.4) <.001
Prior VTE 729 (16) 1534 (17) 1.0 (0.9-1.1) .37
Initial DVT presentation
Proximal DVT 3371 (76) 7573 (84) 0.6 (0.6-0.7) <.001
Bilateral lower limb DVT 93 (2.1) 246 (2.7) 0.8 (0.6-1.0) .03
Initial therapy
LMWH 4317 (97) 8954 (99) 0.3 (0.2-0.4) <.001
LMWH dose, IU/kg/d 164 6 42 180 6 39 d <.001
Fondaparinux 139 (3.1) 83 (0.9) 3.5 (2.6-4.6) <.001
Long-term therapy
Vitamin K antagonists 3139 (71) 6601 (74) 0.8 (0.8-0.9) <.001
LMWH 1207 (27) 2233 (25) 1.1 (1.0-1.2) .009
LMWH dose, IU/kg/d 138 6 48 142 6 51 d .04
CI, Conﬁdence interval; DVT, deep venous thrombosis; IU, international units; LMWH, low-molecular-weight heparin; OR, odds ratio; SD, standard
deviation; VTE, venous thromboembolism.
Continuous data are presented as mean 6 standard deviation and categoric data as number (%).
Table II. Clinical outcome, according to treatment in the hospital or at home
Home therapy (n ¼4456), No. (%) In-hospital therapy (n ¼ 9037), No. (%) OR (95% CI) P value
7-day outcome
Symptomatic PE 12 (0.27) 15 (0.17) 1.6 (0.8-3.5) .21
Recurrent DVT 4 (0.09) 8 (0.09) 1.0 (0.3-3.4) .98
Major bleeding 6 (0.13) 45 (0.50) 0.3 (0.1-0.6) .001
Overall death 4 (0.09) 76 (0.84) 0.1 (0.04-0.3) <.001
Fatal PE 0 7 (0.08) d .06
Fatal bleeding 3 (0.07) 10 (0.11) 0.6 (0.2-2.2) .45
90-day outcome
Symptomatic PE 37 (0.83) 58 (0.64) 1.3 (0.9-2.0) .22
Recurrent DVT 39 (0.88) 100 (1.11) 0.8 (0.5-1.1) .21
Major bleeding 39 (0.88) 149 (1.65) 0.5 (0.4-0.8) <.001
Overall death 72 (1.62) 600 (6.64) 0.2 (0.2-0.3) <.001
Fatal PE 1 (0.02) 20 (0.22) 0.1 (0.01-0.8) .006
Fatal bleeding 7 (0.16) 36 (0.40) 0.4 (0.2-0.9) .02
CI, Conﬁdence interval; DVT, deep venous thrombosis; OR, odds ratio; PE, pulmonary embolism.
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Current guidelines on antithrombotic therapy recom-
mend initial treatment at home over treatment in the hos-
pital for DVT patients with adequate home circumstances.1
Our data revealed that in real life, only one in every three
patients was treated at home, thus suggesting that many
physicians are still concerned about the risks of home ther-
apy. Certainly, the proportion of patients treated at homeprogressively increased during the 10-year period, but 1
in every 2 patients was still initially treated in the hospital
in 2012, as also found in other recent studies.21 Our data
revealed that patients treated at home did not experience
a worse outcome than those treated in the hospital did.
In fact, they had fewer major bleeding events and a lower
mortality. Because patients in both groups were mostly at
home by 7 days, any difference in outcome between groups
should be attributed to the fact that patients who were
Table III. Clinical outcome after propensity score matching
Univariable Multivariable
OR (95% CI) P value OR (95% CI) P value
7-day outcome
Symptomatic PE 2.4 (0.8-6.8) .10 2.4 (0.8-6.8) .10
Recurrent DVT 0.7 (0.2-2.4) .53 0.7 (0.2-2.4) .56
Major bleeding 0.4 (0.1-1.0) .04 0.4 (0.1-1.0) .04
Overall death 0.2 (0.1-0.7) .009 0.2 (0.1-0.7) .01
Fatal PE d d d d
Fatal bleeding 1.5 (0.3-9.0) .66 1.6 (0.3-9.3) .63
90-day outcome
Symptomatic PE 1.3 (0.8-2.1) .33 1.3 (0.8-2.1) .34
Recurrent DVT 0.7 (0.5-1.1) .12 0.7 (0.5-1.1) .12
Major bleeding 0.8 (0.5-1.2) .34 0.9 (0.6-1.4) .56
Overall death 0.4 (0.3-0.5) <.001 0.4 (0.3-0.5) <.001
Fatal PE 0.1 (0.01-0.9) .04 0.1 (0.01-0.9) .04
Fatal bleeding 1.0 (0.4-2.9) 1.00 1.0 (0.4-2.9) .99
CI, Conﬁdence interval; DVT, deep venous thrombosis; OR, odds ratio; PE, pulmonary embolism.
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those treated at home.
During the ﬁrst 7 days of anticoagulation, patients
receiving treatment at home had a similar rate of PE events
(0.27% vs 0.17%), a signiﬁcantly lower rate of major
bleeding (0.13% vs 0.50%), and a lower mortality (0.09%
vs 0.84%) compared with those treated in the hospital.
The lower rate of major bleeding may have been due to
an appropriate identiﬁcation of patients perceived to be at
high risk for bleeding and the lower LMWH doses admin-
istered to patients treated at home. The similar rate of PE
events in patients in both groups reveals the difﬁculties in
identifying at-risk patients. The lower mortality in patients
treated at home may not be explained only because these
patients were younger or had fewer comorbidities; any dif-
ference in baseline characteristics had likely disappeared
after propensity score matching. Clinical experience of
attending physicians may have been of help to identify
low-risk patients to be treated at home. Interestingly, at
the end of the third month, patients receiving treatment
at home from the beginning still had a lower mortality
and a lower rate of symptomatic PE, even after propensity
score matching and multivariable analysis.
In the literature, six randomized clinical trials involving
1708 participants compared home with in-hospital therapy
for patients with acute DVT. As in our study, patients
treated at home with LMWH had fewer VTE recurrences
(relative risk [RR], 0.61; 95% CI, 0.42-0.90) and major
bleeding events (RR, 0.67; 95% CI, 0.33-1.36) and a lower
mortality (RR, 0.72; 95% CI, 0.45-1.15) than those
treated in the hospital with UFH or LMWH had.6 In addi-
tion, treatment at home was cost-effective and preferred by
most patients. However, all these studies had some meth-
odological problems, such as high exclusion rates, partial
hospital treatment of many patients receiving LMWH,
and comparison of UFH in the hospital with LMWH at
home. Our study compared consecutive patients (there
were no exclusion criteria) receiving similar therapies andconﬁrmed that home therapy was associated with a better
outcome.
Our ﬁndings may have several limitations. First, for this
study, home therapy was considered when patients spent
less than 24 hours in the hospital from their arrival to the
emergency department. Certainly, it would be interesting
to compare different durations of hospital stay, but there
is no way to do it with the RIETE database. We gather in-
formation on the date of arrival and the date of discharge,
not the hours of admission and discharge. Second, in
RIETE, we differentiate only between proximal (above
the popliteal vein) and distal DVT. Therefore, there is no
information on the more proximal thrombus extent (ie,
femoral vs iliac vs caval). Third, in the RIETE registry,
there is no information on the type of LMWH used, how
it was dosed, and whether it was administered once a day
or twice a day. We gathered only the daily dose. Fourth, se-
lection bias could have skewed the study sample because
RIETE is a registry and patients were not randomly allo-
cated but received the prescription of their physician’s
choice.14 Finally, every physician had different forms of
approach to home vs in-hospital therapy, and some patients
may not have been properly trained to follow the recom-
mended guidelines for treatment of DVT. However, the
broad range of patients with acute DVT from multiple cen-
ters, countries, and treatment settings enrolled in the
RIETE registry decreased the likelihood of the inclusion
of a skewed population in this study. Our population-
based sample reﬂected the effects of home therapy in
“real-world” clinical care and enhanced the generalizability
of our ﬁndings. Moreover, we used propensity score
matching to make the patient groups comparable accord-
ing to the potential confounders, and we successfully
balanced the observed differences. However, residual con-
founding may still have occurred. Finally, the similar ﬁnd-
ings obtained at 7 and 90 days provided evidence of the
robustness of the study and further strengthened the
soundness of our conclusions. Another strength of this
JOURNAL OF VASCULAR SURGERY
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practice, from a very large number of consecutive patients
with objectively conﬁrmed DVT, in whom a diagnosis of
recurrent VTE had been obtained by strictly applying
objective criteria.
CONCLUSIONS
In summary, the rate of symptomatic PE or major
bleeding during the ﬁrst week of anticoagulant therapy
was low (<1%), but 1 in every 4 such patients died.
Thus, its clinical relevance should not be underestimated.
We consistently found that in-hospital treatment does not
confer any survival advantage over treatment at home.
These data may help safely treat more DVT patients at
home.
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